X-PACT Immunolight (Breast Cancer, Head & Neck Cancer, Melanoma, and Sarcoma)

X-PACT Immunolight (Breast Cancer, Head & Neck Cancer, Melanoma, and Sarcoma)

Es posible que algunos contenidos no estén disponibles en español.

Purpose of this Study

We are doing this study to find out if an experimental drug and device system called X-PACT is a safe and effective treatment for various forms of cancer.

Who Can Participate?

Eligibility

Adults ages 18+ who:
  • Have soft tissue sarcoma, melanoma, breast cancer, or head and neck cancer
  • Still have cancer after treatment with the standard therapies
  • Do not have any other treatment options left
For more information about who can join this study, please contact the study team at elizabeth.sachs@duke.edu

Age Range

8-110

Sex/Genders

Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No

What is Involved?

Description

If you join this study, you will:
  • Be injected with the study treatment (X-PACT) five times
  • Give tumor tissue
  • Have physical exams, blood draws, and urine tests
  • Have a heart scan (ECG)
  • Have imaging scans (X-Rays, MRI and/or CT)
Please visit https://www.immunolight.com/patients to learn more about the study treatment.

Locations

Duke University Hospital
Other

Visit Timing

Weekdays
Evenings

Compensation

Yes

Spanish Materials Available

No

Study Details

Full Title

Phase 1 Study of X-PACT (X-ray Psoralen Activated Cancer Therapy) for Intra-tumoral Injection in Patients with Advanced Head and Neck Cancer, Breast Cancer, Soft Tissue Sarcoma or Melanoma

Study Website

Study Website

Principal Investigator

William
Eward

Protocol Number

PRO00105022

NCT ID

NCT04389281

Phase

I

Enrollment Status

Open to Enrollment
ClinicalTrials.gov